Anne Li September 30th, 2017 email@example.com
In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death. Triple-negative breast cancer is a subtype that does not express hormone receptor or HER2. It occurs in approximately 15 percent of patients with breast cancer. This subtype tends to be more aggressive and targeted therapeutic treatment options are lacking.
See original article at: https://www.sciencedaily.com/releases/2017/09/170926115935.htm